Press Releases
Press Release from Tamir Biotechnologies
Tamir Biotechnology, Inc today announced that it has selected Pharmatech Oncology, Inc. as the Clinical Research Organization to run its upcoming Phase II trial of RANPIRNASE (ONCONASE® in combination with platinum doublet chemotherapy for patients with advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).
Pharmatech Oncology's Presentation at 46th Annual DIA Meeting
Eric Lynam, VP of Business Development for Pharmatech Oncology, led a session at the 46th Annual Drug Information Association Meeting earlier this month. The session was well-attended and generated a great discussion.
Pharmatech Oncology to Present at 46th Annual DIA Meeting
On Wednesday June 16, Pharmatech Oncology will chair a session at the 46th Annual DIA Meeting to discuss patient-focused clinical research systems in the age of personalized cancer medicine. Speakers will include Jeffrey Vacirca MD, Director of Clinical Research at North Shore Hematology/Oncology Associates in East Setauket, NY and Matt Baker, President and CEO of Compass IRB in Mesa, AZ.
Pharmatech Oncology Announces ASCO Abstracts
Pharmatech Oncology announces that abstracts for two studies supported by the company have been accepted for presentations during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, June 4-8, 2010.
Pharmatech Oncology Launches New Data Management Business Unit
Pharmatech Oncology, Inc., a Research Management Organization (RMO), has been selected as one of the presenting companies at the Company Showcase during BIOZONA 2009 – Arizona’s Annual Bioscience Industry Conference at the Sheraton Phoenix Downtown on April 7th in Phoenix, Arizona.
Pharmatech Oncology Selected to Present at Company Showcase at Biozona
Pharmatech Oncology, Inc., a Research Management Organization (RMO) headquartered in Denver, Colorado, announces the launch of their Data Management business unit to the bioscience and pharmaceutical industries.
The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
Pharmatech Oncology has been selected by the Fitzsimons Redevelopment Authority to be a preferred vendor to the Colorado Science + Technology Park at Fitzsimons.
Pharmatech 2.0: Introducing Pharmatech Oncology
Pharmatech, Inc. announces the launch of a new campaign, Pharmatech 2.0, to highlight the company’s focus in oncology, along with other key company developments that will take place in early January 2009.
Matthew B. Wiener Wins Outstanding Researcher Award
Matthew B. Wiener, PharmD, Chief Executive Officer of Pharmatech, Inc., was recently awarded the Outstanding Cancer Leadership Award from the Colorado Cancer Coalition.
Pharmatech Contracts for Five New Just-In-Time Trials
Pharmatech, Inc., a Research Management Organization (RMO), has contracted with five leading pharmaceutical companies to provide research and site management services for their clinical trials using the Just-in-Time (JIT) enrollment strategy.
Pharmatech Teams up with Systems Medicine LLC and The Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
Pharmatech, Inc., a Research Management Organization (RMO), has contracted with Systems Medicine LLC (SML), a subsidiary of Seattle-based Cell Therapeutics, Inc. (CTI), to provide research and site management services for their phase II open-label clinical study for patients with myxoid liposarcoma with a (12;16) translocation.
Pharmatech Presents Preliminary Trial Results at 49th Annual ASH Meeting
Pharmatech, Inc., a Research Management Organization (RMO), will be presenting preliminary data from two clinical trials evaluating combination therapy to treat patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL) at the American Society of Hematology’s Annual Meeting, to be held December 8-11 in Atlanta, Georgia.
Pharmatech Inc. Wins Award
Pharmatech, Inc. is pleased to announce that one of their Project Managers, Heike Newman, MS, MBA, received the Special Recognition Award from the Society of Clinical Research Associates (SoCRA) for her collaboration on an abstract and poster presentation.
OmniComm, Inc. Partnership
OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that it will partner with Pharmatech, Inc., a Research Management Organization (RMO), to build a patient registry database that will improve patient accrual in clinical trials.
Pharmatech Reports Business Results From 2005 - Details Network Model For Growth In 2006
Pharmatech, Inc. is a Research Management Organization (RMO) dedicated to the highest quality of clinical research, while protecting patient care and patient safety. Pharmatech combines the services of Clinical Research Organizations (CROs) with a refined research network of over 1500 investigators, caring for ½ million cancer patients in oncology and urology care.
Pharmatech Management Team Solidifies Personnel Foundation for Operational Excellence
Pharmatech, a Research Management Organization (RMO) within the oncology field of the pharmaceutical research industry, is pleased to announce the hiring of two new executives to the management team. Anders Malm is the new President and Dale Coykendall is the new Chief Financial Officer (CFO).
Pharmatech Presents Positive Clinical Results At The Pan-Pacific Conference
Pharmatech, Inc., a Research Management Organization (RMO), has presented preliminary data from a clinical trial testing the combination of Nipent® and Rituxan® to treat patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL).
Pharmatech Announces Site-Centric Approach
Pharmatech, the only Research Management Organization (RMO) in the pharmaceutical research industry, announces a new site-centric model. The purpose of developing this approach is to better provide customer service in a more personalized manner to Network members involved with Pharmatech.